Fundz

Who to call at CEL-SCI Corporation, and when

Fundz watches for the moments CEL-SCI Corporation starts buying, and tells you who to reach.

  • An alert the day CEL-SCI Corporation raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at CEL-SCI Corporation, from your own LinkedIn network
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

CEL-SCI Renews Partnership with Ergomed for FDA Registration Study of Multikine in Head and Neck Cancer

Oct 01, 2024

Contract Type

partnership

ViennaBiotechnologyHealthcareHealth Care

Description

CEL-SCI Corporation has renewed its collaboration with Ergomed Clinical Research for the upcoming U.S. Food and Drug Administration confirmatory Registration Study of Multikine in head and neck cancer. Ergomed will be providing global comprehensive clinical operations support to ensure the timely and efficient execution of the trial.

Company Information

Company

CEL-SCI Corporation

Location

Vienna, Illinois, United States

About

CEL-SCI is a clinical-stage biotechnology company focused on finding the best way to activate the immune system to fight cancer and infectious diseases. The Company’s lead investigational therapy Multikine completed a pivotal Phase 3 clinical trial involving head and neck cancer, for which the Company has received Orphan Drug Status from the FDA. The Company will be commencing a confirmatory trial for Multikine, with enrollment expected to begin in Q4 2024. The Company has operations in Vienna, Virginia, and near Baltimore, Maryland.

Related People

Eyal
Likely contact at this company
••••••••@••••••••

See Eyal's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for CEL-SCI Corporation's next move

Learn about Strategic plan

Agreement Insights

What this usually means
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies

CEL-SCI Corporation signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.